Compare AbCellera Biologics Inc (ABCL) vs KKR & Co Inc (KKR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs KKR & Co Inc — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while KKR & Co Inc trades at $93.05 (market cap $85.42B). The key difference: KKR & Co Inc is far larger — about 36.3× AbCellera Biologics Inc's market cap, and KKR & Co Inc pays a 0.79% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | KKR | |
|---|---|---|
Market Cap | $2.35B | $85.42B |
Sector | Health | Financials |
52-Week High | $8.12 | $152.16 |
52-Week Low | $2.78 | $83.88 |
Enterprise Value | $1.99B | $10.95B |
Dividend Yield | — | 0.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
KKR trades at $95.14, up 1.39% today, with a bullish technical outlook supported by moving averages. The stock shows strong analyst sentiment with 24 buy ratings and a consensus price target of $127.43. Recent developments include a $1.3 billion renewable energy platform in South Korea and a $4.2 billion acquisition of EDF Power Solutions' North American operations, highlighting strategic growth initiatives. Financials reveal a P/E of 32.64 and net income margin of 14.51%, with Q1 2026 EPS beating expectations at $1.39 versus $1.26 estimated.
The outlook for KKR is positive, driven by expansion in renewable energy and private credit leadership, though risks include integration challenges from acquisitions and market volatility. Earnings growth and strategic deals present upside potential, with the current price offering a 34% discount to the analyst target. Investors should monitor Q2 2026 results due July 30, 2026, for further catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →
